CIK 0001157601 · Large accelerated filer
MADRIGAL PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- MDGL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (267) 824-2827
- Business address
- 1001 CONSHOHOCKEN STATE ROAD, SUITE 2-350, WEST CONSHOHOCKEN, PA
- Former names
- MADRIGAL PHARMACEUTICALS, INC., SYNTA PHARMACEUTICALS CORP
- Open-market buys, last 90 days
- $35,023,032
- in 1 filing
- Open-market sales, last 90 days
- $7,011,938
- in 3 filings, $6.7M under 10b5-1 plans
Net +$28,011,094. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-04-04 | FRIEDMAN PAUL A Director | Sale 10b5-1 | −627 | $244.31 | $153K | 190,779 |
| 2024-04-04 | FRIEDMAN PAUL A Director | Sale 10b5-1 | −2,549 | $245.14 | $625K | 188,230 |
| 2024-04-04 | FRIEDMAN PAUL A Director | Sale 10b5-1 | −1,558 | $246.13 | $383K | 186,672 |
| 2024-04-04 | FRIEDMAN PAUL A Director | Sale 10b5-1 | −737 | $247.14 | $182K | 185,935 |
| 2024-04-04 | FRIEDMAN PAUL A Director | Sale 10b5-1 | −200 | $248.43 | $50K | 185,735 |
| 2024-04-04 | FRIEDMAN PAUL A Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −18,710 | 260,139 | ||
| 2024-04-03 | Taub Rebecca Pres., R&D, and CMO | Option exercise 10b5-1 | +27,845 | $9.45 | $263K | 486,844 |
| 2024-04-03 | Taub Rebecca Pres., R&D, and CMO | Sale 10b5-1 | −135 | $242.00 | $33K | 486,709 |
| 2024-04-03 | Taub Rebecca Pres., R&D, and CMO | Sale 10b5-1 | −2,634 | $243.68 | $642K | 484,075 |
| 2024-04-03 | Taub Rebecca Pres., R&D, and CMO | Sale 10b5-1 | −4,070 | $244.68 | $996K | 480,005 |
| 2024-04-03 | Taub Rebecca Pres., R&D, and CMO | Sale 10b5-1 | −18,917 | $245.34 | $4.6M | 461,088 |
| 2024-04-03 | Taub Rebecca Pres., R&D, and CMO | Sale 10b5-1 | −2,089 | $246.32 | $515K | 458,999 |
| 2024-04-03 | Taub Rebecca Pres., R&D, and CMO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −27,845 | 125,283 | ||
| 2024-04-03 | FRIEDMAN PAUL A Director | Option exercise 10b5-1 | +27,407 | $9.45 | $259K | 213,142 |
| 2024-04-03 | FRIEDMAN PAUL A Director | Sale 10b5-1 | −185 | $242.00 | $45K | 212,957 |
| 2024-04-03 | FRIEDMAN PAUL A Director | Sale 10b5-1 | −2,294 | $243.64 | $559K | 210,663 |
| 2024-04-03 | FRIEDMAN PAUL A Director | Sale 10b5-1 | −4,301 | $244.58 | $1.1M | 206,362 |
| 2024-04-03 | FRIEDMAN PAUL A Director | Sale 10b5-1 | −18,806 | $245.34 | $4.6M | 187,556 |
| 2024-04-03 | FRIEDMAN PAUL A Director | Sale 10b5-1 | −1,821 | $246.31 | $449K | 185,735 |
| 2024-04-03 | FRIEDMAN PAUL A Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −27,407 | 278,849 |
Page 33 of 82 · 1,629 trades